
News|Articles|April 1, 2003
Avandia (rosiglitazone)
This drug from the thiazolidinedione class is now approved for use incombination therapy with insulin, expanding on the existing indicationsas monotherapy and as combination therapy with metformin or sulfonylureas.Rosiglitazone improves sensitivity to insulin in muscle and adipose tissueand inhibits hepatic gluconeogenesis.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Rebate and adherence concerns drive payer reluctance on GLP-1 obesity coverage
2
CagriSema reduces HbA1c, weight across T2D spectrum in REIMAGINE trials | ADA 2026
3
Five years later, personalized mRNA vaccine cuts melanoma recurrence risk by half
4
FDA to review biosimilar of Entyvio
5





























